Selank and Semax compared

An anxiety outcome can sit beside an injury outcome. Giving them a common score is where the trouble begins.

Shared tail, different parents

Both compounds are synthetic heptapeptides with a Pro-Gly-Pro ending intended to slow breakdown. Selank extends tuftsin, an immune-regulatory peptide; Semax extends the ACTH(4-7) sequence and lacks full-length ACTH's cortisol-releasing activity. Their respective molecular review and neurotrophin study approach quite different biology.

Their construction rewards comparison. For effectiveness, I need the experiment's population and endpoint before the resemblance becomes useful.

Measured outcomes

Question	Selank	Semax
What human anxiety result is in this list?	Selank: A small Russian study in generalized anxiety disorder and neurasthenia reported anxiety reduction and mild activation.	Semax: The sources here do not include a comparable human anxiety trial.
Where does BDNF appear?	Selank: Expression increased in rat hippocampus.	Semax: Rat basal-forebrain protein increased at 3 hours; mRNA changes varied across rat brain regions.
What injury outcome was measured?	Selank: The principal clinical result here concerns anxiety.	Semax: Reduced infarct volume and better passive-avoidance retention in rats, plus locomotor recovery after spinal-cord injury in female mice.
What makes interactions a live question?	Selank: GABA-binding effects in rat brain membranes and enzyme inhibition in human plasma outside the body.	Semax: Neurotrophic and broad immune and vascular gene-expression effects in injured rat brain; human drug interactions remain poorly characterized.

I give the Selank anxiety trial priority when the question concerns anxiety in people. I give the Semax injury experiments priority when the question concerns those injury models. That sounds almost too obvious to say, until the labels calm and focus start doing the work of the actual outcomes.

Combination claims

The combination experiment in this source list paired Selank with diazepam in chronically stressed rats. It reported a greater reduction in anxiety-related behavior than either compound alone. It did not test a Selank–Semax regimen in people.

I take the stronger rat response as evidence that an interaction deserves attention. It leaves the safety and usefulness of combining these peptides in humans unresolved. A persuasive case for a combination would need its own human outcomes and safety data; adding the separate compounds' reputations cannot supply them.

Regulatory and practical limits

Neither Selank nor Semax has FDA or EMA approval. Selank's registration is essentially limited to Russia, while Semax is registered as a prescription medicine in Russia and Ukraine. U.S. research-labelled material exists alongside clinician-assessed compounded prescribing, which is a separate patient-specific decision. Research-labelled material is intended for laboratory work and is not intended for human consumption; compounded medicines also lack FDA approval.

Both records are geographically concentrated, largely in Russian research. Independent Western replication is limited, and Semax has no published Western randomized controlled trial. For me, a well-controlled human comparison carries more interest than speculation about which peptide ought to suit which personality. For the individual experiments, continue with Selank or Semax.